Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial

NCT00397813 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00397813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00397813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
March 31, 2018
Enrollment
77 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atypical chronic myeloid leukemia, bcr-abl1 negative, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, essential thrombocythemia, myeloproliferative neoplasm, paroxysmal nocturnal hemoglobinuria, polycythemia vera, polycythemia vera, post-polycythemic myelofibrosis phase, primary myelofibrosis, refractory anemia, refractory anemia with excess blasts, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia and ring sideroblasts